Advertisement

Topics

Tyrosine Protein Kinase CSK C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2 Pipeline Review, H1 2018 [Report Updated: 27022018] Prices from USD $3500

14:41 EDT 16 Apr 2018 | BioPortfolio Reports

Tyrosine Protein Kinase CSK C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2 Pipeline Review, H1 2018


Summary


Tyrosine Protein Kinase CSK C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2 Tyrosineprotein kinase CSK also known as Cterminal Src kinase is an enzyme that, in humans, is encoded by the CSK gene. It plays an important role in the regulation of cell growth, differentiation, migration and immune response. It phosphorylates tyrosine residues located in the Cterminal tails of Srcfamily kinases SFKs. To inhibit SFKs, CSK is recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane. It suppresses signaling by various surface receptors including Tcell receptor TCR and Bcell receptor BCR.


Tyrosine Protein Kinase CSK C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2 pipeline Target constitutes close to 14 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in PreRegistration, Phase III, Phase I, Preclinical and Discovery stages are 1, 2, 1, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Dermatology, Immunology and Infectious Disease which include indications Breast Cancer, Melanoma, HighGrade Glioma, Ovarian Cancer, Solid Tumor, Actinic Solar Keratosis, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Arrhythmias, Bile Duct Cancer Cholangiocarcinoma, Blood Cancer, Chronic Myelocytic Leukemia CML, Chronic Myeloid Leukemia, Colon Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, EpsteinBarr Virus HHV4 Infections, Esophageal Cancer, Fallopian Tube Cancer, Gallbladder Cancer, Gastric Cancer, Glioblastoma Multiforme GBM, Glioma, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Lung Adenocarcinoma, Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Mild Cognitive Impairment, Myocardial Infarction, Nasopharyngeal Cancer, NonSmall Cell Lung Cancer, Osteosarcoma, Peritoneal Cancer, Prostate Cancer, Psoriasis, Recurrent Glioblastoma Multiforme GBM, Renal Cell Carcinoma, Skin Cancer, SmallCell Lung Cancer, Stroke, Thrombosis, Thymoma Thymic Epithelial Tumor and Thyroid Cancer.


The latest report Tyrosine Protein Kinase CSK Pipeline Review, H1 2018, outlays comprehensive information on the Tyrosine Protein Kinase CSK C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Tyrosine Protein Kinase CSK C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2 targeted therapeutics development with respective active and dormant or discontinued projects.


The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase CSK C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2

The report reviews Tyrosine Protein Kinase CSK C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase CSK C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2 targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase CSK C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase CSK C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase CSK C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase CSK C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Tyrosine Protein Kinase CSK C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2 Pipeline Review, H1 2018 [Report Updated: 27022018] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Tyrosine Protein Kinase CSK C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2 Pipeline Review, H1 2018 [Report Updated: 27022018] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...